Third degree AV block primary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
* [[Patients]] on multiple [[AV nodal blocker]] agents (e.g., [[beta-blockers]] and [[calcium channel blockers]]) are at an increased risk for the development of [[atrioventricular (AV) block ]]. | * [[Patients]] on multiple [[AV nodal blocker]] agents (e.g., [[beta-blockers]] and [[calcium channel blockers]]) are at an increased risk for the development of [[atrioventricular (AV) block ]]. | ||
* These [[patients]] should be carefully monitored for [[heart blocks]]. | * These [[patients]] should be carefully monitored for [[heart blocks]]. | ||
*[[Primary prevention]] of [[congenital]] [[complete heart block]] or [[second-degree AV block]] for [[women ]] with [[SLE]] include taking [[hydroxychloroquine]] prior to [[conception]].<ref name="pmid30137589">{{cite journal| author=Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E et al.| title=The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. | journal=Rheumatology (Oxford) | year= 2018 | volume= 57 | issue= suppl_5 | pages= v9-v17 | pmid=30137589 | doi=10.1093/rheumatology/key141 | pmc=6099126 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30137589 }}</ref> | |||
<br /> | <br /> | ||
Latest revision as of 08:56, 24 July 2021
|
Third degree AV block Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Third degree AV block primary prevention On the Web | |
|
American Roentgen Ray Society Images of Third degree AV block primary prevention | |
|
Risk calculators and risk factors for Third degree AV block primary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]
Overview
Effective measurement for primary prevention of atrioventricular block due to dogoxine toxicity in patients with renal insufficiency is avoidance of dehydration, electrolytes imbalance and careful monitoring about heart block.
Primary prevention
- Effective measurement for primary prevention of atrioventricular block due to dogoxin toxicity in patients with renal insufficiency is avoidance of dehydration, and electrolytes imbalance and careful monitoring about heart block.[1]
- In patients with renal insufficiency, potassium, electrolyte disturbances, and dehydration are predisposed to develop digoxin toxicity.
- Careful monitoring of electrolytes, drug levels, and renal function is essential in patients on chronic digoxin therapy.
- Patients on multiple AV nodal blocker agents (e.g., beta-blockers and calcium channel blockers) are at an increased risk for the development of atrioventricular (AV) block .
- These patients should be carefully monitored for heart blocks.
- Primary prevention of congenital complete heart block or second-degree AV block for women with SLE include taking hydroxychloroquine prior to conception.[2]
References
- ↑ Adamantidis MM, Duriez PR, Vincent AC, Dupuis BA (1983). "Digoxin-induced toxicity and experimental atrioventricular block in dogs. Relation between ventricular arrhythmias and oscillatory afterpotentials". J Pharmacol. 14 (3): 333–49. PMID 6632915.
- ↑ Clowse MEB, Eudy AM, Kiernan E, Williams MR, Bermas B, Chakravarty E; et al. (2018). "The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices". Rheumatology (Oxford). 57 (suppl_5): v9–v17. doi:10.1093/rheumatology/key141. PMC 6099126. PMID 30137589.